Daicel Corporation (Head Office: Kita-ward, Osaka; President & CEO: Misao Fudaba) has signed an agreement for the 100% acquisition of Lomapharm group companies (LOMA Holding GmbH, Lomapharm Rudolf Lohmann GmbH KG, Lomapharm Verwaltungs GmbH, hereinafter “Lomapharm”), a German pharma contract development and manufacturing organization (CDMO) on August 1, 2018. Seller is the Luxembourg based PE Investor Lenbach Equity Opportunities I. SCSp (“LEO I”). Lomapharm will become a 100% subsidiary of Daicel Corporation upon completion of the transaction.
With more than 135 years of experience in the pharmaceutical manufacturing, Lomapharm, an independent mid-sized CDMO, offers development, production, packaging and release of different dosage forms to its customers such as large pharmaceutical companies, UN organizations and NGOs.
Daicel Corporation has been active in medical business, mainly providing pre-mix excipients such as GRANFILLER-D® and DiSPERZiSTA®. This transaction will enable us to enter into drug formulation business and also expand our excipient business. By closely working with Lomapharm, Daicel Corporation endeavours to further accelerate growth of medical and healthcare business, one of our focused areas of new business.
LEO I is an investor active in the DACH Region and is exclusively advised by DUBAG Investment Advisory GmbH. LEO I is focused on the acquisition and development of mid-cap companies in special situations, such as corporate spin-offs, carve outs and family owned companies with succession issues.
＜Overview of Lomapharm＞
Entity structure : LOMA Holding GmbH
Lomapharm Rudolf Lohmann GmbH KG (operating entity)
Lomapharm Verwaltungs GmbH (administrative entity)
Established in : 1878
Address : Emmerthal, Niedersachsen, Germany
Lines of business: Contract Manufacturing and development of pharmaceutical and health supplemental products
Key product : Film coated tablets, sugar coated tablets, eye and nasal drops,
supplements such as Lomacare
Employees : 150
Investor Relations, Daicel Corporation